The Big Changes Coming to Medical Labs: Digital Pathology and AI Working Together

Medical laboratories handle some of the most critical work in healthcare. Every day, tissue samples from biopsies, surgeries, and screenings arrive for examination. Pathologists study these samples to detect cancer, infections, and inflammatory disease, and their findings guide treatment decisions that can alter or save lives.

For decades, the process stayed largely the same: thin slices of tissue on glass slides, stained to highlight structures, viewed through a microscope. That system served medicine well, but it carried built-in limits — slow sharing of cases, heavy physical storage demands, risk of damage or loss, and reliance on whichever expert happened to be available. Labs are now shifting to digital pathology, scanning slides into high-resolution digital images and pairing that with AI tools trained to assist the read. The change touches everyone involved — pathologists, technicians, oncologists, researchers, and patients.

The Move from Glass to Digital

Whole-slide scanners are the core of digital pathology. These machines capture an entire glass slide as one large digital file, often at resolutions clear enough to view individual cells. Once scanned, the image lives on a network or cloud server, and pathologists open it on a monitor, moving around the tissue as they would under a microscope — zooming smoothly from low to high power, adjusting brightness and contrast instantly, drawing measurements directly on screen.

Sharing becomes trivial. A pathologist in one hospital uploads a file, and a specialist across the country — or the world — opens the exact same view seconds later, no courier, no risk of a broken slide, no customs delay when a case crosses borders. Storage problems shrink too: hospitals that once devoted entire rooms to slide archives now keep years of cases on servers that fit in a closet, and finding a prior biopsy for comparison takes moments instead of hours.

How AI Actually Fits In

Digital images provide the raw material AI needs, and several tools trained on this data have moved well past the research stage into real, FDA-cleared clinical use.

These tools assist pathologists in three concrete ways. First, AI scans new images and flags suspicious regions, so a pathologist starts each case with highlighted areas needing closer attention rather than a blank screen — speeding up routine work and reducing the odds of missing something on a busy day. Second, AI performs measurements that used to require manual counting or estimation: mitotic figures for tumor grading, the percentage of cells staining positive for a biomarker, tumor boundary outlines — adding real objectivity, since different pathologists reviewing the same case now arrive at more consistent numbers. Third, AI helps prioritize the case queue, moving biopsies with malignancy-suggestive features to the top of the list.

The partnership stays clear throughout: every FDA-cleared tool in this category currently requires a pathologist’s final sign-off. None has been cleared to replace clinical judgment — they reduce tedium and add consistency so experts can focus on the genuinely hard calls.

Personal Experience: Where the Real Time Savings Show Up

The instinctive assumption is that AI’s biggest benefit is catching cancer a human might miss. That happens, but the more consistent, day-to-day value shows up somewhere less dramatic: routine biomarker quantification. Manually counting Ki-67 or estimating PD-L1 staining percentage across a slide is tedious, repetitive work that’s genuinely hard to do with perfect consistency case after case, especially late in a long shift. Handing that specific task to software — while the pathologist still reviews and confirms every result — is where labs report the most reliable time savings, not from AI making dramatic catches on ambiguous cases, but from removing the grinding, error-prone parts of an otherwise routine day.

A Typical Day in a Digital Lab

Tissue blocks arrive from surgery or clinic. Technicians cut and stain sections, then load slides into the scanner in batches. Digital images appear in the lab information system almost immediately, and AI algorithms run automatically on each new case — within minutes, annotations and preliminary measurements are ready. Pathologists log in, sometimes from home, pull up assigned cases, review the flagged areas, adjust as needed, write reports, and sign out electronically, with the final diagnosis landing directly in the patient’s electronic health record. Turnaround for routine biopsy results has dropped from three-to-five days to one-to-two in many labs running this workflow.

Benefits Across Specialties

Oncology sees some of the largest gains — consistent tumor grading helps guide therapy choice and trial enrollment, and biomarker quantification (PD-L1, HER2, estrogen receptor status) informs decisions about immunotherapy, targeted drugs, or hormone treatment. Dermatology practices are following closely behind, particularly with tools like PathAssist Derm extending the same approach to skin lesion review. Gastroenterology groups apply the same digital workflow to colon and esophageal biopsies, and hematology labs now examine digital bone marrow samples and blood smears the same way. Research and training benefit too — residents get exposure to thousands of digital cases instead of the limited physical sets any single department could offer.

Costs and Challenges

Upfront cost remains the biggest barrier. High-quality scanners run into the hundreds of thousands of dollars, and software, storage, and network upgrades add to the total — a real hesitation point for smaller hospitals and independent labs. Staff need training: technicians learn new scanning protocols, and pathologists adjust to screen-based review, which feels unfamiliar to some at first. IT teams carry real responsibility for data security and regulatory compliance here, overlapping directly with the broader challenges covered in AI’s growing role in mobile and data security, since patient imaging data demands the same high-stakes protection as other sensitive health information moving through cloud systems.

Algorithm performance is also genuinely uneven across populations — models trained mostly on certain demographic groups can underperform on others, a documented, acknowledged limitation across current FDA-cleared tools, not a hypothetical risk. Labs address this by validating any AI tool against their own patient mix before relying on it clinically. Despite these hurdles, costs are trending down as scanner prices fall, cloud platforms reduce on-site server needs, and more pathologists graduate from programs that already teach digital methods.

What’s Coming Next

Integration with other data types is the next frontier — linking pathology images to genomic sequencing, radiology scans (a parallel trend to the multimodal shift seen in DXA scan technology), and clinical notes to predict treatment response more accurately and surface personalized options earlier. Predictive tools will flag recurrence risk based on subtle image features, and global reference centers will keep expanding access to expert-level review for regions with few trained pathologists.

FAQ

Does AI replace pathologists in digital labs?
No — every FDA-cleared digital pathology AI tool currently requires a pathologist’s final review and sign-off. The technology assists with detection and measurement; it doesn’t make the diagnosis independently.

What was the first FDA-cleared AI tool for pathology?
Paige Prostate, which received FDA de novo authorization in 2021 for flagging suspicious regions in prostate core biopsies.

How much faster are results with digital pathology and AI?
Many labs report routine biopsy turnaround dropping from three-to-five days to one-to-two days after adopting a digital, AI-assisted workflow.

Why is AI performance sometimes inconsistent across different patient groups?
Models are trained on specific case collections, and if those collections underrepresent certain populations, accuracy can drop for patients outside that training data — a known limitation labs address through their own local validation before clinical use.

Is digital pathology only useful for cancer diagnosis?
No — it’s expanding into dermatology, gastroenterology, and hematology, and supports research and training even where cancer detection isn’t the primary use case.

What’s the biggest barrier to labs adopting this technology?
Upfront cost — scanners alone can run into the hundreds of thousands of dollars, before software, storage, and staff training are factored in.

Takeaway

Before evaluating any AI pathology tool, check its specific FDA clearance scope and validation population — a tool cleared for prostate biopsy detection isn’t validated for dermatology, and a model’s published accuracy may not hold on a lab’s particular patient mix without local validation first.